Halozyme Therapeutics, Inc.

NasdaqGS:HALO Stock Report

Market Cap: US$7.2b

Halozyme Therapeutics Future Growth

Future criteria checks 4/6

Halozyme Therapeutics is forecast to grow earnings and revenue by 17.3% and 13% per annum respectively. EPS is expected to grow by 18.9% per annum. Return on equity is forecast to be 80.4% in 3 years.

Key information

17.3%

Earnings growth rate

18.9%

EPS growth rate

Biotechs earnings growth27.2%
Revenue growth rate13.0%
Future return on equity80.4%
Analyst coverage

Good

Last updated14 Jan 2025

Recent future growth updates

Recent updates

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Might Not Be As Mispriced As It Looks

Jan 28
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Might Not Be As Mispriced As It Looks

Halozyme: Recent Approvals Alter My Appetite

Dec 31

Halozyme Therapeutics (NASDAQ:HALO) Seems To Use Debt Rather Sparingly

Nov 28
Halozyme Therapeutics (NASDAQ:HALO) Seems To Use Debt Rather Sparingly

Halozyme: Fabless Or Not, The Stock Is Now A Steal On Evotec Deal

Nov 20

Halozyme: Looking For More Growth Following Record Q3 Earnings

Nov 05

Not Many Are Piling Into Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Yet

Oct 29
Not Many Are Piling Into Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Yet

Halozyme Therapeutics: Behind The Pullback

Oct 22

Halozyme Therapeutics, Inc.: Significantly Undervalued Growth Based On Current Fundamentals

Aug 14

Halozyme Therapeutics (NASDAQ:HALO) Has A Rock Solid Balance Sheet

Aug 13
Halozyme Therapeutics (NASDAQ:HALO) Has A Rock Solid Balance Sheet

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Not Flying Under The Radar

Jul 17
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Not Flying Under The Radar

Halozyme Therapeutics: The Story Brightens

Jun 07

Is Halozyme Therapeutics (NASDAQ:HALO) Using Too Much Debt?

Apr 26
Is Halozyme Therapeutics (NASDAQ:HALO) Using Too Much Debt?

Halozyme's Strategic Partnerships Fueling Next-Gen Therapeutics

Apr 10

Does Halozyme Therapeutics (NASDAQ:HALO) Deserve A Spot On Your Watchlist?

Apr 05
Does Halozyme Therapeutics (NASDAQ:HALO) Deserve A Spot On Your Watchlist?

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Doing What It Can To Lift Shares

Mar 15
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Doing What It Can To Lift Shares

Earnings Update: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Feb 23
Earnings Update: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Halozyme Therapeutics: A Reasonable Value In An Overvalued Market

Jan 26

Earnings and Revenue Growth Forecasts

NasdaqGS:HALO - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20271,696918N/AN/A4
12/31/20261,452781N/AN/A7
12/31/20251,1835795765408
12/31/20241,0044384374479
9/30/2024947392393403N/A
6/30/2024873337408420N/A
3/31/2024863319424431N/A
12/31/2023829282373389N/A
9/30/2023781254354369N/A
6/30/2023774234293306N/A
3/31/2023705182264279N/A
12/31/2022660202235240N/A
9/30/2022581211238240N/A
6/30/2022487366290292N/A
3/31/2022472435287289N/A
12/31/2021443403298299N/A
9/30/2021463409265268N/A
6/30/2021412229150152N/A
3/31/2021331163116119N/A
12/31/20202681295355N/A
9/30/202020022-24-22N/A
6/30/2020180-40-60-58N/A
3/31/2020164-80-89-86N/A
12/31/2019196-72-89-85N/A
9/30/2019203-40-55-48N/A
6/30/2019182-43-43-38N/A
3/31/2019178-51-36-32N/A
12/31/2018152-80-54-49N/A
9/30/2018281469193N/A
6/30/201831976N/A132N/A
3/31/201831868N/A134N/A
12/31/201731763N/A134N/A
9/30/2017166-88N/A-35N/A
6/30/2017134-120N/A-64N/A
3/31/2017134-116N/A-60N/A
12/31/2016147-103N/A-50N/A
9/30/2016160-71N/A-50N/A
6/30/2016149-67N/A-58N/A
3/31/2016159-37N/A-36N/A
12/31/2015135-32N/A-37N/A
9/30/2015113-42N/A-23N/A
6/30/2015107-38N/A-19N/A
3/31/201582-57N/A-44N/A
12/31/201475-68N/A-48N/A
9/30/201457-85N/A-62N/A
6/30/201459-84N/A-61N/A
3/31/201455-91N/A-56N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: HALO's forecast earnings growth (17.3% per year) is above the savings rate (2.6%).

Earnings vs Market: HALO's earnings (17.3% per year) are forecast to grow faster than the US market (15.1% per year).

High Growth Earnings: HALO's earnings are forecast to grow, but not significantly.

Revenue vs Market: HALO's revenue (13% per year) is forecast to grow faster than the US market (8.9% per year).

High Growth Revenue: HALO's revenue (13% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: HALO's Return on Equity is forecast to be very high in 3 years time (80.4%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/31 22:53
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Halozyme Therapeutics, Inc. is covered by 34 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
James BirchenoughBarclays
Robert WassermanBenchmark Company